Roopal Thakkar
Insider Reports History
- Location
- North Chicago, IL
- Signature
- /s/ T.O. Odutayo, Attorney-in-Fact for Roopal Thakkar
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Roopal Thakkar:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | EVP, R&D and CSO | Common Stock, $0.01 par value | 52,376 | $12,155,422 | $232.08 | 27 Feb 2026 | Direct |
| AbbVie Inc. | EVP, R&D and CSO | Option (Right to buy) | 21,937 | $2,337,500 | $93.50 | 18 Feb 2026 | Direct |
| AbbVie Inc. | EVP, R&D and CSO | Common Stock, $0.01 par value | 2,998 | $669,333 | $223.26 | 27 Feb 2026 | Profit sharing trust |
Insider Reports Filed by Roopal Thakkar
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 27 Feb 2026 | 1 | -$1,865,227 | 4 | EVP, R&D and CSO | 03 Mar 2026, 18:14 |
| ABBV | AbbVie Inc. | 18 Feb 2026 | 5 | $0 | 4 | EVP, R&D and CSO | 20 Feb 2026, 18:36 |
| ABBV | AbbVie Inc. | 28 Feb 2025 | 1 | -$959,084 | 4 | EVP, R&D and CSO | 04 Mar 2025, 17:00 |
| ABBV | AbbVie Inc. | 13 Feb 2025 | 5 | $0 | 4 | EVP, R&D and CSO | 18 Feb 2025, 17:00 |
| ABBV | AbbVie Inc. | 28 Feb 2024 | 1 | -$879,557 | 4 | SVP, CMO, GLOBAL THERAPEUTICS | 01 Mar 2024, 17:50 |
| ABBV | AbbVie Inc. | 15 Feb 2024 | 5 | $0 | 4/A | EVP, R&D and CSO | 07 Feb 2025, 16:00 |
| ABBV | AbbVie Inc. | 14 Dec 2023 | 0 | $0 | 3 | SVP, Global Therapeutics & CMO | 22 Dec 2023, 16:13 |